Development of Low Molecular Weight Ligands for Integrin αvβ3

Chem Pharm Bull (Tokyo). 2022;70(4):293-299. doi: 10.1248/cpb.c21-01085.

Abstract

We designed and synthesized non-peptide organic molecular ligands for integrin αvβ3. Candidate ligands featured amidino analog and carboxy groups as binding sites on either side of a spacer, which consisted of benzophenone or an analog, such as diphenyl sulfide, diphenyl sulfoxide, diphenyl sulfone, or diphenyl ether. Competitive binding assays to integrin αvβ3 with respect to [125I]echistatin were used to determine inhibitory activity of the synthetic ligands. Ligands bearing 2-aminobenzimidazoyl and glycyl groups separated by a benzophenone spacer demonstrated more potent binding than did a linear Arg-Gly-Asp (RGD) tripeptide that represents the native integrin αvβ3 binding motif. Ligands possessing 2-aminobenzimidazoyl and carboxy groups and diphenyl sulfoxide or diphenyl ether spacers inhibited binding of [125I]echistatin with IC50 values similar to that of the linear RGD tripeptide.

Keywords: [125I]echistatin; integrin αvβ3; non-peptide; synthetic ligand.

MeSH terms

  • Amino Acid Sequence
  • Binding Sites
  • Integrin alphaVbeta3* / chemistry
  • Integrin alphaVbeta3* / metabolism
  • Ligands
  • Molecular Weight

Substances

  • Integrin alphaVbeta3
  • Ligands